BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 12243818)

  • 1. Dose response in prostate cancer with 8-12 years' follow-up.
    Hanks GE; Hanlon AL; Epstein B; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):427-35. PubMed ID: 12243818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer.
    Pinover WH; Hanlon AL; Horwitz EM; Hanks GE
    Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):649-54. PubMed ID: 10837947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
    Kaminski JM; Hanlon AL; Horwitz EM; Pinover WH; Mitra RK; Hanks GE
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):888-92. PubMed ID: 11958880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of nonpalpable PSA-detected adenocarcinoma of the prostate with 3-dimensional conformal radiation therapy.
    Horwitz EM; Hanlon AL; Pinover WH; Hanks GE
    Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):519-23. PubMed ID: 9635697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy.
    Anderson PR; Hanlon AL; Patchefsky A; Al-Saleem T; Hanks GE
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):1087-92. PubMed ID: 9719119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions.
    Hanks GE; Hanlon AL; Schultheiss TE; Pinover WH; Movsas B; Epstein BE; Hunt MA
    Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):501-10. PubMed ID: 9635695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.
    Pollack A; Smith LG; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):507-12. PubMed ID: 10974469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy.
    Anderson PR; Hanlon AL; Horwitz E; Pinover W; Hanks GE
    Cancer; 2000 Dec; 89(12):2565-9. PubMed ID: 11135217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation.
    Anderson PR; Hanlon AL; Movsas B; Hanks GE
    Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1025-30. PubMed ID: 9392540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques.
    Horwitz EM; Hanlon AL; Pinover WH; Anderson PR; Hanks GE
    Cancer; 2001 Sep; 92(5):1281-7. PubMed ID: 11571744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer.
    Galalae RM; Kovács G; Schultze J; Loch T; Rzehak P; Wilhelm R; Bertermann H; Buschbeck B; Kohr P; Kimmig B
    Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):81-90. PubMed ID: 11777625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
    Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer.
    Fukunaga-Johnson N; Sandler HM; McLaughlin PW; Strawderman MS; Grijalva KH; Kish KE; Lichter AS
    Int J Radiat Oncol Biol Phys; 1997 May; 38(2):311-7. PubMed ID: 9226317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group.
    Lattanzi JP; Hanlon AL; Hanks GE
    Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):569-73. PubMed ID: 9231681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy.
    Bonin SR; Hanlon AL; Lee WR; Movsas B; al-Saleem TI; Hanks GE
    Cancer; 1997 Jan; 79(1):75-80. PubMed ID: 8988729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.